R. Abdelrahman; T. Musa; I. Arbab; Mohsen Hussein Suliman; E. O. Ahmed; Asma Noureldaim Mohamed; Hassan Hussein Musa; Mohammed M. Jalal; Sahar Ibrahim Gasmallah

Jan 1, 2025Journal of Obesity1 influential

2025PubMedDirectly related

Role of Liraglutide in weight management and reproductive health in women with obesity and PCOS- A critical review of the evidence.

Shetty S; Bannur Karunakara M; Kristipati RR; Kalthur G; Kumari S

Jan 1, 2025F1000Research

2024CrossrefDirectly related0 citations

Glucagon-like Peptide 1 Receptor Agonists and Obesity Associated with Eating Disorders

Riccardo Dalle Grave

Nov 18, 2024IJEDO

2024OpenAlexDirectly related44 citations

Incretin-based therapies for the treatment of obesity-related diseases

Irene Caruso; Angelo Cignarelli; Gian Pio Sorice; Sebastio Perrini; Francesco Giorgino

Nov 6, 2024npj Metabolic Health and Disease

2024OpenAlexDirectly related39 citations

Use of SGLT2 Inhibitors vs GLP-1 RAs and Anemia in Patients With Diabetes and CKD

Jia-Chian Hu; Shih‐Chieh Shao; Daniel Hsiang‐Te Tsai; Albert Tzu-Ming Chuang; Kuan‐Hung Liu; Edward Chia‐Cheng Lai

Mar 4, 2024JAMA Network Open

2024CrossrefDirectly related26 citations

Management of type 2 diabetes, obesity, or nonalcoholic steatohepatitis with high‐dose GLP‐1 receptor agonists and GLP‐1 receptor‐based co‐agonists

Ronald M. Goldenberg; Jeremy D. Gilbert; Priya Manjoo; Sue D. Pedersen; Vincent C. Woo; Julie A. Lovshin

Mar 1, 2024Obesity Reviews

2024PubMedDirectly related

Oral Adverse Effects of Semaglutide Therapy: A Narrative Review.

Al-Zawawi AS

Jan 1, 2024Journal of International Society of Preventive & Community Dentistry

2024CrossrefDirectly related0 citations

Reprogramming of GLP-1 Response at Prediabetes for the Prevention of Type 2 Diabetes: The Role of Albumin and GLP-1 Receptor Agonists

Amr Ahmed

Jan 1, 2024Cell & Cellular Life Sciences Journal

2023OpenAlexDirectly related124 citations

The association between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: reports to the Food and Drug Administration Adverse Event Reporting System (FAERS)

Roger S. McIntyre; Rodrigo B. Mansur; Joshua D. Rosenblat; Angela T.H. Kwan

Dec 13, 2023Expert Opinion on Drug Safety

2023OpenAlexDirectly related246 citations

GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach

Jingyue Wang; Quanwei Wang; Xinyu Yang; Wei Yang; Dong-Rui Li; Jingyu Jin; Hui-Cong Zhang; Xianfeng Zhang

Feb 1, 2023Frontiers in Endocrinology

2022OpenAlexDirectly related51 citations

Potential Roles of Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs) in Nondiabetic Populations

Dan Xu; Ankith Nair; Charlie Sigston; Chau Ho; Jia Li; Daya Yang; Xinxue Liao; Wei Chen; Ming Kuang; Yanbing Li; Christopher M. Reid; Haipeng Xiao

Nov 16, 2022Cardiovascular Therapeutics

2022CrossrefDirectly related2 citations

504-P: Success of Aligned Clinician–Patient Education Improves Clinicians’ Ability to Use GLP-1 RAs in Practice and Patients’ Understanding of GLP-1 RAs

AMY LARKIN; ANNE LE

Jun 1, 2022Diabetes

Page 19 of 21Showing 217-228 of total 251 results.

1...181920 21

GLP-1 receptor agonists for obesity treatment — Research Evidence and Topic... | Kritoma